Ampreloxetine’s Phase 3 failure in multiple system atrophy is the third disappointing clinical trial outcome for the Theravance Biopharma drug. The biotech will now wind down all R&D and explore options that could include the sale of the company.
The post Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D appeared first on MedCity News.
